Treatment of T-Cell Lymphoma using 10-propargyl-10-deazaaminopterin
First Claim
Patent Images
1. A method for treatment of T cell lymphoma comprising administering to a human patient diagnosed as having a T cell lymphoma a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaaminopterin.
2 Assignments
0 Petitions
Accused Products
Abstract
T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m2 per dose.
-
Citations
8 Claims
- 1. A method for treatment of T cell lymphoma comprising administering to a human patient diagnosed as having a T cell lymphoma a composition comprising a therapeutically effective amount of 10-propargyl-10-deazaaminopterin.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/249
-
CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/519 ortho- or peri-condensed wi...A61K 31/525 Isoalloxazines, e.g. ribofl...A61K 31/7068 having oxo groups directly ...A61P 35/00 Antineoplastic agents
